March 5, 2021 Clinical Trials

NEW study for adults 18 years and older with a diagnosis of psoriasis. Must have history of at least 6 months on Consyntex or Talz. No prior use of Skyrizi. No investigational drug use within 30 days. No major surgeries within 12 weeks, or major planned surgeries. You are being asked whether you would like to voluntarily participate in a research study of a drug called risankizumab (SkyriziTM).

This research study involves the use of an approved drug called risankizumab (SkyriziTM) to treat moderate to severe psoriasis. This study is being run in approximately 50 research centers in 9 countries and is expected to enroll approximately 250 subjects.

If you decide to participate, you will be in this study for up to 64 weeks. The study comprises 3 periods: There will be a 30-day Screening Period, a 52-week open-label study period and a 20-week follow-up period following the last dose of study drug scheduled at Week 40 visit (weeks 40-52 of the open-label period will also be weeks 1-12 of the follow-up period). The open-label period means that you, your study doctor and AbbVie know that what study treatment you are receiving.

You may need to come in for additional (unscheduled) visits if necessary, as determined by your study doctor. If you are eligible to receive study treatment, you will receive 2 injections of active risankizumab 75 mg (150 mg total dosage) subcutaneously (SC) at Weeks 0 and 4 visits, and then every 12 weeks (q12w) until the last dose at Week 40 visit. At any time, you may choose to discontinue from the study and end study participation early, or your study doctor may discontinue your participation for any reason at any time.

AbbVie is sponsoring this study. Being in this study does not replace your regular medical care. AbbVie may stop this study prematurely, either in its entirety or at any study site, for reasonable cause, provided that written notice is submitted in advance of the intended study stop.


March 5, 2021 Clinical Trials

Arlington Research Center is looking for children and adults, aged 6 years and up who have eczema, to participate in a clinical research study evaluating an investigational cream. This study includes up to 5 visits for 2 months.

Studies for youth and adults. Must have a history of atopic for at least 3 months for youth 6-17 years of age, and for at least 6 months for adults 18 years and older. Study patients previously on the ARQ-151 are excluded.

How can you participate?

Inquire about how you can participate in this study today.



March 5, 2021 Clinical Trials

NEW study for adults 18 and older. Topical cream and at-home phototherapy system. Must have facial vitiligo. Subjects with vitiligo on the hands, forearms, or elbows may treat areas in addition to the face with the cream. Begins in mid-March.

How can you participate?

Inquire about how you can participate in this study today.

TO LEARN MORE ABOUT THE VITILIGO STUDY, CONTACT: or call 817-795-7546 ext. 339


December 30, 2020 Clinical Trials

We know life with Hidradenitis Suppurativa isn’t always easy.

There are many unanswered questions surrounding the causes of HS and the painful and distressing symptoms it triggers in the body. With limited approved medical treatment options available, it’s important to keep looking for potential answers.

For this reason, the Ivy Clinical Research Study is investigating 3 different possible treatment options to assess the benefits each could offer to people with moderate to severe HS.

The Ivy Study may be an option for you if:*

  • you have a diagnosis of moderate to severe HS
  • you are 18 – 75 years of age
  • you have HS lesions in two different locations on your body

*There are other requirements for participation in the study. The study doctor will be able to explain these to you.


July 29, 2020 Clinical Trials

Adults 18-75 years old may qualify for this 12-week (or potentially longer) study. 6 months of clinical diagnosis is required. This study is for patients that have a skin condition known as Plaque Psoriasis (“Psoriasis”).

The purpose of this study is to understand how well tapinarof 1% cream works in treating your Psoriasis and to get more information about tapinarof 1% cream’s safety. In this study about 500 people in the United States and Canada will be taking part. Tapinarof is an investigational cream.

There will be 2 (two) groups in the study. One group will get the tapinarof 1% cream, the other group will get the vehicle cream. A computer will put you as a study participant to one of the groups by chance (like a roll of the dice). Neither you nor the study doctor can choose a group. You have a 66.6% chance of being placed in the tapinarof 1% cream group and a 33.3% chance of being placed in the vehicle cream group.

After the screening study visits, if you qualify to take part in the study, you will be scheduled to see the study doctor at their office on Day 1 (Baseline), Week 2, Week 4, Week 8, Week 12, and Week 16. You might have to visit the study doctor at other times (unscheduled visits) if your Psoriasis gets worse. During the visits, you will have tests, and answer questions about any changes to your health.

At the Week 12 visit, if you qualify, you can choose to take part in a longer study (long-term) that lasts 40 weeks (about 9 months). All participants in the long-term study will use tapinarof 1% cream (open-label). You will have to sign an Informed Consent Form to participate in the open-label long-term study.

Call 817-795-7546 or email if you think you would like to participate in this study.


July 28, 2020 Clinical Trials

Another new topical study for patients 12 years and older. This trial runs 13 weeks.

Seborrheic dermatitis is a common skin condition that often affects the scalp, causing symptoms that range from dry flakes (dandruff) to yellow, greasy scales with reddened skin. Seborrheic dermatitis can also affect other oily areas of the body, such as the face, upper chest, and back.

If you are 12 or older and have seborrheic dermatitis on your scalp, face, or body, you may qualify to participate in a new clinical research study. The study is for an investigational topical foam, applied once daily for seborrheic dermatitis.

As part of the study participants will be randomly assigned (by chance) to use either the active investigational foam (2 in 3 chance) or an inactive foam (1 in 3 chance). The inactive foam looks just like the investigational foam, but has no active ingredient. Neither you nor your doctor will know which foam you receive. This is a common technique in clinical studies, as it helps researchers understand the effects of the investigational medication.

Call 817-795-7546 or email if you think you would like to participate in this study.


June 2, 2020 Clinical Trials

Hidradenitis Suppurativa (injection)
– Adults 18 years and older may qualify for a new injection study.

To parcipate you must:

  • Have had signs and symptoms of hidradenitis suppurativa for at least 6 months
  • Have hidradenitis suppurativa bumps (or lesions) in or on at least 2 different areas of your body
  • Have previously taken antibiotics for the treatment of hidradenitis suppurativa

There are other criteria that you will need to meet before you can join the study. Your study doctor will discuss these with you to find out whether you can take part.

Once enrolled in the study, you will receive either the investigational study drug, bimekizumab, or placebo – a placebo looks similar to the study drug but contains no active medication. You will be randomly allocated (like drawing straws) to one of four groups; you will have a 1 in 7 chance of getting placebo for the first 16 weeks, and then, for the remaining 32 weeks you will receive the investigational study drug, for a total of 48 weeks of treatment. Neither you nor the study team will know if you are taking the study drug or placebo during the first part of the study. This ensures that the results from the tests are handled in the same way.

The study drugs will be given by a subcutaneous (under the skin) injection in your lower abdomen (stomach), thigh, or upper arm. Each injection will last less than 20 seconds. Your study doctor will ensure that, during the injection procedure, you are not able to see which study drug you are receiving. This is called ‘maintaining the blind’.
Participants are expected to be in the study for 53 weeks (up to 5 weeks screening plus 48 weeks of study treatment); during this period you will be required to visit the study center approximately 27 times.

Call 817-795-7546 or email if you think you would like to participate in this study.

Copyright © 2020 . All rights reserved. Website Designed by Gott Marketing